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Abstract
Limited-stage small-cell lung cancer (SCLC) occurs in only one third of patients with SCLC,
but it is potentially curable. Combined-modality therapy (chemotherapy and radiotherapy)
has long been the mainstay of therapy for this condition, but more recent data suggest a role
for surgery in early-stage disease. Prophylactic cranial irradiation seems to improve
outcomes in patients who have responded to initial therapy. This review addresses the
practical aspects of staging and treatment of patients with limited-stage SCLC.

INTRODUCTION
In theUnited States, theproportionof smallcell lung cancers (SCLCs) has decreased
from approximately 25% of all lung cancers
in 1993 to approximately 13% in 2002.1
This decline is likely related to changes in
smoking patterns and habits in North
America and Europe.2 Although the incidence of SCLC is decreasing in the United
States and Japan, it is unclear if the same
holds true around the globe.1,3 Approximately two thirds of patients with SCLC
are diagnosed with advanced disease.4 The
remaining patients are diagnosed at a stage
where their disease may be curable. This
review focuses on the management of
patients with limited-stage disease, a
proportion of whom can be cured with
aggressive multimodality therapy.
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STAGING
Because systemic chemotherapy is the
mainstay of treatment for all patients with
SCLC, the main clinical purpose of staging
is to determine whether thoracic irradiation should be incorporated in conjunction with chemotherapy for localized
disease. Two systems are commonly used
to stage SCLC: TNM classification,4 which

Copyright © 2016 by American Society of Clinical Oncology

is identical to that used for non–small-cell
lung cancer, and the Veterans Administration Lung Study Group limited
disease–extensive stage system.
The International Association for the
Study of Lung Cancer defines limited stage
as absence of distant metastatic disease.5
According to this schema, limited-stage
disease is confined to the ipsilateral
hemithorax and contralateral mediastinal
and supraclavicular nodes and ipsilateral
pleural effusion (irrespective of whether
cytology is positive), whereas extensivestage disease includes disease in the
contralateral hemithorax and distant
metastases.
Despite this, the staging of patients
with ipsilateral pleural effusion and
supraclavicular node and contralateral
mediastinal lymph node involvement is
debated. Most trials for limited-stage disease tend to exclude patients with isolated
pleural effusions,6,7 but survival of patients
with isolated pleural effusions seems to
be similar to that of other patients with
limited-stage SCLC.8 Although older
studies showed that supraclavicular lymph
node involvement predicted slightly inferior
survival,9 the International Association for
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the Study of Lung Cancer staging project found no significant difference in outcome between N2 and N3 disease4;
the greatest difference in outcome was between N1 and N2
nodal involvement.
MANAGEMENT
Initial Treatment
The current standard of care for limited-stage SCLC is chemotherapy and concurrent thoracic radiotherapy. This multimodality approach was proven superior to chemotherapy
alone in the 1990s. A meta-analysis by Pignon et al10 examined
13 different trials that randomly assigned patients to chemotherapy or chemotherapy plus thoracic radiotherapy. In
this analysis, there was a 5.4% improvement in overall survival
(OS) at 3 years with the addition of thoracic radiotherapy.10,11
Chemotherapy
SCLC is extremely chemosensitive,12 with response rates of
approximately 65%. Multiple agents with different mechanisms of action have shown activity against SCLC. These
include platinum agents (cisplatin, carboplatin), camptothecins (topotecan, irinotecan), podophyllotoxins (etoposide), anthracyclines (doxorubicin, epirubicin, amrubicin),
alkylating agents (cyclophosphamide, ifosfamide), taxanes
(paclitaxel, docetaxel), and vinca alkaloids (vincristine).
Initial trials found high response rates with cyclophosphamide, doxorubicin, and vincristine (CAV) or cyclophosphamide, epirubicin, and vincristine.13,14 However, after
the introduction of etoposide, the combination of etoposide
with cisplatin (EP) demonstrated superior response rates
compared with CAV.15,16 Also, EP was better tolerated and is
thus the regimen of choice for initial treatment of SCLC.
The standard treatment regimen involves four to six
cycles of chemotherapy with EP.17 However, benefit from
this regimen seems mainly confined to patients younger than
55 years old, with increasing adverse outcomes in patients age
70 years or older.14 With cisplatin causing an increase in
toxicity in the elderly, one could consider carboplatin in that
population as an alternative.18
Thoracic radiotherapy
Chemotherapy alone results in poor local disease control, with
75% to 90% of patients developing intrathoracic failure.19 In
contrast, thoracic radiotherapy can provide local control,
because this disease is radiosensitive; however, thoracic
112
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radiotherapy alone does not have a major impact on overall
disease control.20
Two meta-analyses concluded that a combination of
thoracic radiotherapy and chemotherapy produced a small but
definite improvement in survival. As described earlier, Pignon
et al10 showed the addition of thoracic radiotherapy decreased
the relative risk for death by 14% as compared with chemotherapy alone (P 5 .001). Another meta-analysis of 11
randomized trials also showed a 5.4% improvement in the 2year survival rate with thoracic radiotherapy (P , .05).21
A Canadian population-based retrospective study found
that combined-modality therapy improved median and 2-year
survival as compared with chemotherapy alone (15.1 months
and 32% v 14.3 months and 26.9%, respectively).22 Of note,
when thoracic radiotherapy is administered, it is important
that it be compliant with chemotherapy, or the survival benefit
may be lost.23
Even though the data support the use of a multimodality
approach with chemotherapy and thoracic radiotherapy,
the radiotherapy schedule and total radiation dose have been
continuous sources of debate. Multiple studies have been
conducted comparing early versus late thoracic radiotherapy
(Table 1).6,7,23-27 Although the chemotherapy regimens and
timing varied in these studies, the overall results were
inconclusive.
Several meta-analyses have tried to answer this question,
again with no definitive conclusion. Fried et al28 showed a
small but statistically significant benefit of early compared
with late thoracic radiotherapy in terms of 2-year OS. This
benefit was more pronounced when either hyperfractionated
radiotherapy or platinum-based chemotherapy were used.
However, another meta-analysis suggested that although
there was no difference between early or late thoracic radiotherapy with regard to OS, there was a small but significant
improvement in 5-year OS with early thoracic radiotherapy
when only trials using platinum-based chemotherapy were
considered (odds ratio, 0.64; 95% CI, 0.44 to 0.92; P 5 .02).29
This was even more pronounced when the overall duration
of thoracic radiotherapy was less than 30 days. A Cochrane
review found no significant difference between approaches in
2- or 5-year survival.11 These authors concluded that the effect
of the timing of chest radiotherapy on survival was uncertain.
Another source of controversy is the optimal dose of
radiation. A retrospective analysis of patients enrolled in three
consecutive chemoradiotherapy trials, treated with 45, 55, or
65 Gy, found similar local control and OS. This suggested that a
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Table 1. Timing of Thoracic Radiotherapy
Timing of Radiotherapy (No. of
Patients)

Median OS
(Months)

5-Year OS (%)

First Author

Chemotherapy

Early

Late

Early

Late

Early

Late

Perry6

CAV1 etoposide

Day 1 (125)

Day 64 (145)

13

14.5

6.6

12.8

Work7

CAV 3 6/EP 3 3 (radiotherapy with EP)

Day 1 (99)

Week 18 (100)

10.7

12.9

10

10

Skarlos24

Carboplatin and etoposide

Cycle 1 (42)

Cycle 4 (39)

17.5

17

22*

13*

Murray25

CAV/EP

Week 3 (155)

Week 15 (153)

21.2

16

22

13

Jeremic26

Carboplatin and etoposide (radiotherapy) 1 EP

Week 1 (52)

Week 6 (51)

34

26

30

15

Takada27

EP

Day 2 (114)

After cycle 4 (114)

27.2

19.7

23.7

18.3

Spiro23

CAV/EP

Cycle 2 (159)

Cycle 6 (166)

13.7

15.1

14*

19*

Abbreviations: CAV, cyclophosphamide, doxorubicin, and vincristine; EP, etoposide plus cisplatin; OS, overall survival.
*Three-year survival.

dose of at least 45 Gy would be needed to obtain adequate local
control.30 However, higher doses (56 to 60 Gy administered
in a single daily fractionation scheme) have been shown to
improve tumor control.31,32
Hyperfractionated radiotherapy (twice daily) improves
local control by applying higher doses of radiation administered in a shorter time. A randomized phase III trial that
randomly assigned patients with limited-stage SCLC to either
1.8 Gy once daily over 5 weeks or accelerated 1.5 Gy twice daily
for 3 weeks concurrent with four cycles of EP showed that
patients receiving the accelerated twice-daily schedule had
better median(23 v 19 months) and 5-year OS (26% v 16%) but
had an increased incidence of grade 3 esophagitis or feeding
tube placement (27% v 11%).33 A criticism of this study has
been that the two radiation doses used were not biologically
equivalent.
A recent retrospective analysis using the National Cancer
Database found that patients receiving radiation using three
different fractionation schemes (45 Gy in 30 fractions, 70 Gy in
35 fractions, and 61.2 Gy in 34 fractions) had similar outcomes.34 To answer this question, there are two phase III
studies currently ongoing. The CALGB 30610/RTOG 0538
study (ClinicalTrials.gov identifier NCT00632853) by Cancer
and Leukemia Group B and Radiation Therapy Oncology
Group began as a three-arm study comparing hyperfractionated thoracic radiotherapy (1.5 Gy twice per day to a
total dose of 45 Gy) versus 70 Gy in 2-Gy daily fractions versus
61.2-Gy concomitant boost thoracic radiotherapy. After a
prespecified interim analysis, the concomitant boost arm
Copyright © 2016 by American Society of Clinical Oncology

was stopped, and the study now compares hyperfractionated
thoracic radiotherapy with 70 Gy administered in 2-Gy daily
fractions. Another similar trial, CONVERT (Concurrent Once
Daily Versus Twice Daily Radiotherapy for Limited Stage
Small Cell Lung Cancer), conducted by the United Kingdom
National Cancer Research Institute (ClinicalTrials.gov identifier NCT00433563), comparing standard thoracic radiotherapy (45 Gy at 1.5 Gy twice daily) with 70 Gy at 2- Gy daily
thoracic radiotherapy with concurrent EP, has completed
accrual, and results are pending. Until the results of these
trials are available, both these approaches can be considered
equivalent.

Surgical resection
Until recently, there has not been a role for surgery in the
management of patients with SCLC. However, emerging
data have suggested a role for surgical resection as part of
multimodality therapy in limited-stage SCLC. A prospective
study has reported 5-year survival rates up to 68%, typically
in patients without nodal disease, with surgical resection.35
Schreiber et al36 reviewed the SEER database and found that
patients with SCLC who underwent surgery had better
survival for both localized and regional disease. This is
especially promising because approximately 4% of lung
cancers presenting as a solitary pulmonary nodule are
SCLCs.37 A study analyzing the SEER database noted 5-year
survival rates of greater than 50% in patients with stage I
disease who underwent a lobectomy.38 Unfortunately,
Volume 12 / Issue 2 / February 2016

n

jop.ascopubs.org

113

Almquist, Mosalpuria, and Ganti

details of systemic therapy are not available in these
patients.
A recent retrospective analysis of 277 patients with limitedstage SCLC compared outcomes after surgical resection with
those after conventional nonsurgical treatments.39 Surgical
resection was associated with significantly better 5-year
survival in patients with clinical stage I disease (62% v 25%;
P , .01). Although outcomes in patients with stage II or
III disease were not significantly different, a propensity
score–matched pair analysis of patients with stage II or III
disease showed improved 5-year survival with surgical
resection (P 5 .04).
Thus, patients with clinical stage T1-2 N0 disease are
candidates for lobectomy. There are emerging data
supporting a possible role for surgery in patients with N1 and
possibly N2 disease, but this approach cannot be routinely
recommended; it should be determined on a case-by-case
basis. There is still a need for additional prospective studies that
will help define the scope of surgical resection in the management of limited-stage SCLC.
Prophylactic Cranial Irradiation
The brain is a common site of metastasis in SCLC, and
approximately 45% patients who achieve a complete response
with initial therapy will present with brain metastases as the
only site of relapse.40
Two separate meta-analyses concluded that prophylactic
cranial irradiation decreased the incidence of brain metastases
by 52% to 54% and improved survival by16% to18% inpatients
who had achieved a complete response to therapy.41,42 In their
meta-analysis of seven clinical trials in patients who were in
complete remission after initial therapy, Aupérin et al41
showed a significant 3-year survival benefit in those who
received prophylactic cranial irradiation (20.7% v 15.3%;
P 5 .01). A retrospective analysis of North Central Cancer
Treatment Group trials of prophylactic cranial irradiation
in patients with stable disease or better showed that after
induction therapy, the median OS increased from 14 to
17 months with prophylactic cranial irradiation (P 5 .0045).43
In a retrospective SEER database analysis, which included
7,995 patients with limited-stage SCLC, Patel et al44 showed an
increase in 5-year survival with prophylactic cranial irradiation (19% v 11%; P , .001). On the basis of these results,
standard practice now includes prophylactic cranial irradiation for patients with a complete (or good partial) response to
initial therapy.
114
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The optimal dose and fraction size for prophylactic cranial
irradiation are unclear. A randomized trial compared a prophylactic cranial irradiation dose of 25 Gy in 10 fractions with
high-dose prophylactic cranial irradiation (36 Gy in 18 fractions once daily or 36 Gy in 24 fractions using 1.5 Gy twice
daily) in 720 patients with limited-stage SCLC who had
achieved a complete response after chemotherapy and thoracic
radiotherapy.45 This study showed no significant reduction of
brain metastases with higher-dose prophylactic cranial irradiation, but it did show a significant increase in mortality.
Therefore, at the present time, prophylactic cranial irradiation
at 25 Gy in 10 fractions should remain the standard of care.
One of the major concerns with the use of prophylactic
cranial irradiation is long-term neurotoxicity. Studies have not
shown a significant neurocognitive decline specifically
attributable to prophylactic cranial irradiation.40,46 In a retrospective analysis of 98 patients, those who received prophylactic cranial irradiation had a significant improvement in
mean Q-TWiST (quality time without symptoms and toxicity)
survival.47 In another similar analysis that evaluated qualityadjusted life expectancy, prophylactic cranial irradiation
offered a benefit over no prophylactic cranial irradiation (mild
toxicity, 4.31 and 3.70 quality-adjusted life-years; substantial
toxicity, 4.09 and 3.70 quality-adjusted life-years, respectively).48 The results of these analyses would suggest a benefit
to prophylactic cranial irradiation without undue toxicity;
however, well-designed clinical trials with this specific
objective in mind are needed.
Relapsed or Refractory SCLC
Despite the excellent response rates seen initially, the majority
of patients experience relapse; many of these are candidates
for second-line treatment. Patients who relapse more than
3 months after the end of first-line treatment are considered
chemotherapy sensitive.49 Response rates to second-line
therapy are approximately 25% in chemotherapy-sensitive
patients, as opposed to approximately 10% in patients who
have experience early relapse or have primary refractory
disease.49
Once patients experience relapse after initial therapy, the
goal of treatment is mainly palliative. If disease is controlled
for more than 6 months, a second course of EP can be
considered.49,50 Topotecan, a water-soluble, semisynthetic
derivative of camptothecin, has demonstrated antitumor
activity in relapsed and refractory SCLC. In a randomized
phase III study of 210 patients with sensitive relapse,

Journal of Oncology Practice
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Table 2. Therapeutic Regimens
Modality

Schedule

First-line chemotherapy

Cisplatin 60 mg/m2 IV day 1; etoposide 120 mg/m2/d IV days 1-3; repeat every 3 weeks
Cisplatin 80 mg/m2 IV day 1; etoposide 100 mg/m2/d IV days 1-3; repeat every 3-4 weeks
Cisplatin 80 mg/m2 IV day 1; etoposide 80 mg/m2/d IV days 1-3; repeat every 3 weeks
Cisplatin 25 mg/m2 IV days 1-3; etoposide 80 mg/m2/d IV days 1-3; repeat every 3-4 weeks
Cisplatin 60 mg/m2 IV day 1; etoposide 120 mg/m2/d IV days 1-3; repeat every 3 weeks
Carboplatin AUC 5 IV day 1; etoposide 100 mg/m2/d IV days 1-3; repeat every 4 weeks
Carboplatin AUC 5 IV day 1; etoposide 80 mg/m2/d IV days 1-3; repeat every 3-4 weeks

Thoracic radiotherapy

1.5 Gy twice daily (at least 6 hours apart) in 3 weeks for total dose of 45 Gy
1.8 Gy daily over 6.5 weeks to total dose of at least 60 Gy

Prophylactic cranial irradiation

25 Gy in 10 daily fractions
30 Gy in 10-15 daily fractions
24 Gy in eight daily fractions

Relapsed disease

Topotecan 2.3 mg/m2/d orally on days 1-5; repeat every 3 weeks
Topotecan 1.5 mg/m2/d IV on days 1-5; repeat every 3 weeks
Amrubicin 40 mg/m2/d IV on days 1-3; repeat every 3 weeks
Paclitaxel 80 mg/m2 IV weekly for 6 weeks; repeat every 8 weeks
Paclitaxel 175 mg/m2 IV day 1; repeat every 3 weeks
Etoposide 50 mg/m2 orally daily for 21 days*; repeat every 4 weeks
Docetaxel 100 mg IV day 1; repeat every 3 weeks
Temozolomide 75 mg/m2 orally daily for 21 days*; repeat every 4 weeks

Abbreviation: IV, intravenously.
*Doses should be rounded to the nearest 50-mg dose.

topotecan improved time to progression and median survival
compared with CAV.51 Moreover, topotecan had greater
symptom control and decreased interference with daily
activities. The oral formulation of topotecan seems to have
similar efficacy.52
Amrubicin, a synthetic 9-amino anthracycline, has shown
promising activity in SCLC.53 A phase III trial comparing
amrubicin with topotecan in 637 patients found that although
OS was similar, the subset of patients with refractory disease
treated with amrubicin had better survival (6.2 v 5.7 months;
P 5 .047).53 Patients treated with amrubicin had significant
symptom improvement, but they also had increased incidence
of infection and febrile neutropenia. The common chemotherapy and radiation regimens used in the management of
SCLC are summarized in Table 2.
Copyright © 2016 by American Society of Clinical Oncology

Multiple other agents, including taxanes, irinotecan,
vinorelbine, temozolomide, bendamustine, and gemcitabine,
have shown modest activity in relapsed and refractory SCLC.
The programmed death-1 inhibitors pembrolizumab and
nivolumab seem promising in initial studies.
OUTCOMES
Although the majority of patients with limited-stage SCLC
experience relapse after initial treatment, there is a cohort of
patients who can have long-term survival (Fig 1). Older studies
have demonstrated a doubling of 5-year survival in these
patients from 5% in 1973 to 10% in 1998.1 A more recent
analysis of the SEER database based on receipt of prophylactic
cranial irradiation showed that 3-year OS for patients with
limited-stage SCLC receiving prophylactic cranial irradiation
Volume 12 / Issue 2 / February 2016
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Survival (probability)

1
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was 23% compared with 17% for those not receiving prophylactic cranial irradiation.54 Interestingly, when these
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patients alive at 1, 2, and 3 years after diagnosis was 23%, 39%,
and 52%, respectively, suggesting that a proportion of patients
could possibly be considered to have been cured of their
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In conclusion, combined-modality therapy is the mainstay
of management of limited-stage SCLC. Concurrent chemotherapy with a combination of platinum and etoposide and
thoracic radiotherapy should be recommended for all patients
deemed fit for therapy. For patients who have extensive
intrathoracic disease, it may be reasonable to administer two
cycles of chemotherapy before starting radiotherapy. Surgical
resection followed by adjuvant chemotherapy may benefit
patients with early-stage disease. Prophylactic cranial irradiation has been shown to decrease the incidence of brain
metastasis and improve OS in patients who do not experience
progression during initial therapy. Multiple agents have shown
modest activity in the second-line setting.
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